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http://dx.doi.org/10.1016/j.pedneo.2Peripheral apheresis has become a safe procedure to collect hematopoietic stem cells, even in
pediatric patients and donors. However, the apheresis procedure for small and sick children is
more complicated due to difficult venous access, relatively large extracorporeal volume,
toxicity of citrate, and unstable hemostasis. We report a small and sick child with refractory
medulloblastoma, impaired liver function, and coagulopathy after several major cycles of
cisplatin-based chemotherapy. She successfully received large-volume leukapheresis for
hematopoietic stem cell collection, although the patient experienced severe coagulopathy
during the procedures. Health care providers should be alert to this potential risk.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
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Several clinical problems have been encountered when
collecting peripheral blood stem cells (PBSCs) from very
small children, such as difficult venous access, relatively
large extracorporeal blood volume, citrate toxicity, coa-
gulopathy, unstable cardiovascular status, and difficult
assessment of the patient’s performance and activity.ed by Elsevier Taiwan LLC. All rights reserved.
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ture that discuss hematopoietic stem cell collection by
leukapheresis in very small children.1,2 Most collections
have been performed in relatively healthy children as
autologous donors. High-dose chemotherapy with stem cell
rescue has been used to successfully treat small pediatric
patients with refractory brain tumors.3 Harvest of PBSCs
from small and sick children with impaired function of the
liver, kidney, or other organs is more difficult. We report
successful large-volume leukapheresis (LVL) for stem cell
collection in a small and sick child with refractory medul-
loblastoma, coagulopathy, and liver function impairment
after several cycles of heavy chemotherapy. We describe
the efficiency and safe management for coagulopathy
during the procedure in this patient who had a high risk for
intracranial hemorrhage.2. Case Report
A one-and-a-half-year-old female child weighing 12 kg with
unresectable and refractory cerebellum medulloblastoma
was prepared for further high-dose chemotherapy with
autologous PBSC rescue. The patient had received five
major chemotherapy cycles of cisplatin and cyclophospha-
mide, which were modified from the protocol of the Chil-
dren’s Cancer Group study CCG-9921, with good initial
response but later relapse.4 The same protocol was also
used for PBSC mobilization. This child had suffered from
several episodes of neutropenic fever, septic shock, coa-
gulopathy, and deep wound infections after chemotherapy.
Her laboratory tests showed chronic liver dysfunction prior
to the leukapheresis, including low serum total protein
4.9 mg/dL, low albumin 2.97 mg/dL, high total bilirubin
3.36 mg/dL, prolonged prothrombin time (PT) 14.8 seconds
(normal range 9.6e11.4 seconds), prolonged activated
partial thromboplastin time (aPTT) 46.9 seconds (normal
range 25e33 seconds), and increased D-dimer 5.3 mg/L
(normal range < 0.55 mg/L).
The peripheral circulating immature cell (CIC) count of
white blood cells (WBCs) was used as an indicator for the
suitable timing to perform the PBSC collection. We
placed two central venous catheters (7F) in this child,
with one in the left femoral vein and the other in the
right jugular vein, on the day prior to leukapheresis.
Granulocyte colony-stimulating factor (G-CSF) 10 mg/kg
had been given for 10 days since the onset of neu-
tropenia. On the day of harvest, the laboratory data
showed WBC count 42.8  109/L, hemoglobin 9.8 g/dL,
platelet count 101  109/L, promyelocytes 1.0%, myelo-
cytes 3.5%, bands 1.0%, segments 79%, lymphocytes 10.5%,
monocytes 5% and CICs 2354/mL in the WBC differentials,
ionized calcium 5.12 mg/dL, PT 13.2 seconds, and aPTT
40.6 seconds. We used COBE Spectra version 6.1 autoPBSC
apheresis systems (Gambro BCT, Lakewood, CO, USA) to
collect the autologous PBSCs for this child. One unit of
packed red cells was used as the priming blood to set up
the interface between the machine and the patient. The
packed red cells were warmed to reduce the risk of hy-
pothermia. The estimated processed total blood volume
(TBV) of the procedure was 900 mL. A bolus of heparin
45 U/kg was given over 10 minutes immediately prior to thefirst collection. Anticoagulant citrate dextrose solution A
(ACD-A) combined with heparin was used as the anticoag-
ulant agent (1200 U heparin in 500-mL bag of ACD-A) during
the process. We used ACD-A at a ratio of 1:30 to whole
blood as recommended and adjusted the ACD-A infusion
rate according to the inlet flow rate. However, PT was
prolonged to 15.0 seconds and the aPTT to >120 seconds
2 hours after the beginning of the procedure. Therefore,
we discontinued heparin and used ACD-A only for the next
two cycles of apheresis. There was no platelet clump for-
mation without concurrent heparin infusion. PT was then
reduced to 14.5 seconds and aPTT to 39.8 seconds after
completion of the procedure. The inlet flow rate was 10
mL/min at the beginning, and finally attained 20 mL/min
during the rest of the procedure. Prophylactic calcium
gluconates were given at the end of every hour with calglon
at 1 mL/kg during the apheresis to prevent citrate-related
hypocalcaemia. The apheresis was completed after a 3.5-
hour run time and a total of 3.6 L blood had been pro-
cessed (4 times TBV). The 48-mL final harvest product
showed total nucleated cells were 9.71  108 cells/kg and
CD34þ cells 2.13  106/kg. Two hours after completion of
the procedure, hemoglobin was 7.5 g/dL, platelet count
60  109 /L, ionized calcium 5.91 mg/dL, PT 14.5 seconds,
and aPTT 39.8 seconds.
We repeated this procedure on the next day and needed
to discontinue heparin again after the third cycle of the
apheresis due to the severely prolonged PTT (>120 sec-
onds). A total of 3.1 L blood was processed, and the final
product contained total nucleated cells 3.81  108/kg and
CD34þ cells 7.23  105/kg. Two hours after completion of
the procedure, PT was 14.8 seconds and aPTT reduced to
49.1 seconds. Vital signs were stable, and no bleeding
episode was observed during either procedure. The patient
was fully awake during the procedures, without use of any
anesthetic drugs.3. Discussion
Medulloblastoma is the second most common pediatric
brain tumor, with a dismal outcome. Recently, several
groups have reported an increased survival rate with high-
dose chemotherapy and stem cell rescue.5,6 However, PBSC
collection in small children is a therapeutic and techno-
logical challenge, especially in children with severe
complications, such as impaired liver function and coagul-
opathy from previous chemotherapy, and the potential risk
of intracranial hemorrhage.7,8
Only a few reports have mentioned the harvest of
autologous PBSCs from very small children with brain tu-
mors after cisplatin-based chemotherapy.3
By disease-based chemotherapy, with G-CSF for stem
cell mobilization and CICs as the time indicator for harvest,
we were able to acquire enough stem cells even after the
patient had undergone heavy chemotherapy. The acute
subtraction of the large extracorporeal volume in small
children often leads to hypotension, hypothermia, hypo-
volemia, or even cardiovascular collapse.2,9 This patient
tolerated the procedures well without any sign of unstable
cardiovascular function after initial red cell priming prior to
leukapheresis.
Leukapheresis and coagulopathy in a child 213Typically, ACD-A alone or combined with heparin is used
for anticoagulation during leukapheresis for PBSC collec-
tion. Most researchers use ACD-A in combination with
heparin for small children to reduce citrate toxicity.10,11 It
allows the ACD-A ratio to be increased to 1:25e30 to
decrease the total dose of citrate infused. However, these
combined anticoagulants might be unsuitable for small and
sick patients after they have undergone heavy chemo-
therapy, especially in those with liver dysfunction and
coagulopathy. The small and sick patient described here
had just recovered from severe infection, sepsis-related
coagulopathy, and unstable homeostasis. With close moni-
toring of blood clump formation, we discontinued heparin
and used ACD-A only for the rest of the procedure due to
severely prolonged aPTT. Both collections were completed
smoothly without blood clump formation or bleeding epi-
sodes, indicating ACD-A alone could serve as an effective
anticoagulant and might be suitable in small and sick chil-
dren with liver dysfunction. Worel et al have reported their
experience of using ACD-A only for the collection of PBSCs
in small children weighing < 17 kg.12 We used prophylactic
calcium gluconate infusion during apheresis to prevent
hypocalcemia. No hypocalcemia or the associated symp-
toms or signs were found, indicating hypocalcemia due to
LVL was preventable in this patient.
LVL is defined as the processing of 3e6 times TBV of the
patient in a single procedure compared to 2e3 times TBV in
the conventional apheresis. LVL has the advantage of col-
lecting higher yields of progenitor cells. Therefore, LVL is
used for planned autologous tandem transplant and in a
heavily treated patient to allow for higher-dose CD34þ cell
collection.13 Several reports have suggested that LVL can be
safely performed in small children weighing < 15 kg.14 As in
our small sick child, LVL with a total of four times TBV was
performed safely without any obvious complications.
Finally, regarding PBSC collection in patients with liver
dysfunction and coagulopathy, there are no reports
addressing this issue in the related literature. In view of
chronic liver dysfunction, various hemostatic abnormalities
could be found. Decreased production of blood coagulation
factors by the liver play a key role in altered homeostasis.
Thrombocytopenia, chronic disseminated intravascular
coagulation, accelerated fibrinolysis, and platelet
dysfunction could also alter the delicate balance of
hemostatsis. Keeping the patient awake and calm during
the procedures help us to observe clinical changes; espe-
cially in brain tumor patients with high risk of intracranial
bleeding. ACD-A alone might be adequate in these patients
to maintain anticoagulation status during LVL for PBSC
collection.
In conclusion, we performed successful LVL for PBSC
collection in a very small child without any obvious com-
plications. With delicate planning, the cooperation of
multiple disciplinary teams and close monitoring of clinical
data, especially coagulation status, LVL can be safely
performed in small and sick children with refractory
medulloblastoma and unstable hemostasis after heavychemotherapy at an experienced hospital. Any change in
the coagulation profile should be closely observed in pa-
tients with chronic liver dysfunction.References
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